Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 12, 2015 02:00 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Announces Favorable Topline Results From Thorough QT Clinical Trial of SD-809

SD-809 Met Primary Outcome Measure, Showed No Clinically Significant QT Prolongation NDA Submission Planned by Mid-2015 LA JOLLA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Auspex...
January 05, 2015 16:07 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex to Present at the J.P. Morgan Healthcare Conference

LA JOLLA, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
December 22, 2014 16:00 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Added to the NASDAQ Biotechnology Index

LA JOLLA, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
December 16, 2014 16:05 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease

Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After...
December 01, 2014 09:00 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex to Present at the Piper Jaffray Healthcare Conference

LA JOLLA, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
November 10, 2014 08:30 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals Reports Third Quarter 2014 Results and Business Highlights

LA JOLLA, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
November 06, 2014 12:35 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Huntington's Disease

LA JOLLA, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
October 30, 2014 07:00 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia

LA JOLLA, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
August 27, 2014 16:01 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex to Present at the Baird 2014 Healthcare Conference

LA JOLLA, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel...
August 18, 2014 07:00 ET | Source: Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals Completes Enrollment in Phase 3 Registration Clinical Trial of SD-809 in Chorea Associated With Huntington's Disease

LA JOLLA, Calif., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel...